CompoZr® Zinc Finger Nucleases
SAFC® recognizes that one of the most time consuming and costly endeavors biopharmaceutical companies face is creating robust, efficient cell lines. Zinc Finger Nuclease (ZFN) technology, allows easy creation of novel CHO cell lines with precise and heritable gene additions, deletions or modifications.
ZFNs are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome by creating double-strand breaks in DNA at user-specified locations. Double-strand breaks are important for site-specific mutagenesis in that they stimulate the cell's natural DNA-repair processes, namely homologous recombination and Non-Homologous End Joining (NHEJ). Using well-established and robust protocols, these cellular processes can be harnessed to generate precisely targeted genomic edits resulting in cell lines, with targeted gene deletions (knock-outs), integrations (knock-ins), or modifications.
SAFC has created catalog ZFNs for use in the biopharmaceutical industry. They are completely animal component free (ACF) and have been fully validated and quality tested.
ZFNs may be used to create the customer's choice of stable genetically engineered cell lines or organisms with gene deletions, integrations and modifications. The CompoZr Custom ZFN Service provides researchers with a validated pair of ZFNs that have been custom designed and assembled to edit their target gene in a highly specific manner or you can use our Cell Design Studio group (CDS) who can do the work for you. Click here to learn more about SAFC's CDS group.
CompoZr Zinc Finger Nucleases for CHO Cells
New CHOZN® ZFN-Modified CHO Cell Lines
SAFC is proud to offer a newly created series of zinc finger nuclease (ZFN) modified CHO cell lines with characteristics that are attractive in a platform cell line to biopharmaceutical developers and manufacturers. Learn more here about these novel cell lines and find out how they can you take your molecule to clinic faster.
New CHOZN® Platform
SAFC has created the first ever commercially available cell line platform that allows for faster, simpler selection and scale up of high producing clones for the production of recombinant protein drugs. Learn more about this streamlined production solution.